What is the official website of Intertek Pharmaceutical Services ?

The official website of Intertek Pharmaceutical Services is https://www.intertek.com/pharmaceutical/.

What is Intertek Pharmaceutical Services's cybersecurity risk score?

Intertek Pharmaceutical Services has an AI-generated cybersecurity risk score of 754 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Intertek Pharmaceutical Services experienced?

According to Rankiteo, Intertek Pharmaceutical Services currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Intertek Pharmaceutical Services been affected by any supply chain cyber incidents ?

According to Rankiteo, Intertek Pharmaceutical Services has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Intertek Pharmaceutical Services have SOC 2 Type 1 certification ?

According to Rankiteo, Intertek Pharmaceutical Services is not certified under SOC 2 Type 1.

Does Intertek Pharmaceutical Services have SOC 2 Type 2 certification ?

According to Rankiteo, Intertek Pharmaceutical Services does not hold a SOC 2 Type 2 certification.

Does Intertek Pharmaceutical Services comply with GDPR ?

According to Rankiteo, Intertek Pharmaceutical Services is not listed as GDPR compliant.

Does Intertek Pharmaceutical Services have PCI DSS certification ?

According to Rankiteo, Intertek Pharmaceutical Services does not currently maintain PCI DSS compliance.

Does Intertek Pharmaceutical Services comply with HIPAA ?

According to Rankiteo, Intertek Pharmaceutical Services is not compliant with HIPAA regulations.

Does Intertek Pharmaceutical Services have ISO 27001 certification ?

According to Rankiteo,Intertek Pharmaceutical Services is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Intertek Pharmaceutical Services operate in ?

Intertek Pharmaceutical Services operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Intertek Pharmaceutical Services have ?

Intertek Pharmaceutical Services employs approximately None employees people worldwide.

Does Intertek Pharmaceutical Services own any subsidiaries ?

Intertek Pharmaceutical Services presently has no subsidiaries across any sectors.

How many LinkedIn followers does Intertek Pharmaceutical Services have ?

Intertek Pharmaceutical Services's official LinkedIn profile has approximately 3,460 followers.

What is the NAICS classification code for Intertek Pharmaceutical Services ?

Intertek Pharmaceutical Services is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Intertek Pharmaceutical Services have a Crunchbase profile ?

No, Intertek Pharmaceutical Services does not have a profile on Crunchbase.

Does Intertek Pharmaceutical Services have a LinkedIn profile ?

Yes, Intertek Pharmaceutical Services maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/intertek-pharma.

How many cybersecurity incidents has Intertek Pharmaceutical Services experienced ?

As of October 20, 2026, Rankiteo reports that Intertek Pharmaceutical Services has not experienced any cybersecurity incidents.

How many peer or competitor companies does Intertek Pharmaceutical Services have ?

Intertek Pharmaceutical Services has an estimated 5,775 peer or competitor companies worldwide.

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

IPS

Boost Score +25 with badge (5 left)

754

/1000

Fair

779

/1000

Fair

Intertek Pharmaceutical Services Vendor Cyber Rating & Cyber Score

intertek.com

Add Your Compliance Badge

Contract pharmaceutical & biopharmaceutical GLP/GCP/GMP laboratory services, global supply chain GXP auditing services and regulatory guidance supporting drug development and production. Bringing quality and safety to life, we offer Total Quality Assurance expertise to help you to meet and exceed quality, safety and regulatory standards.

IPS

Intertek Pharmaceutical Services CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

IPS Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for IPS

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Intertek Pharmaceutical Services in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Intertek Pharmaceutical Services in 2026.

Incident Types IPS vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Intertek Pharmaceutical Services in 2026.

Incident History - IPS (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Intertek Pharmaceutical Services Subsidiaries

IPS

Pharmaceutical Manufacturing

Website: https://www.intertek.com/pharmaceutical/

Company Size: 1,001-5,000 employees

IntertekInternational Trade and Development

Intertek Middle EastInternational Trade and Development

Intertek BangladeshInternational Trade and Development

Intertek BrazilInternational Trade and Development

Intertek FranceInternational Trade and Development

Loading…

Intertek Pharmaceutical Services Similar Companies

MANKIND PHARMA LTD

mankindpharma.com

Mankind Pharma, one of the top 5 leading pharmaceutical companies in India, started its journey in 1995. Today, we have an employee base of over 20,000 and are racing towards $1 Billion. At Mankind, we aspire to aid the community in leading a healthy life by formulating, developing, commercializing, and delivering affordable and accessible medicines that satisfy urgent medical needs. We take great pride in the success of our products ranging from Pharma, OTC and FMCG brands like Manforce Condoms, Manforce Tablets, Manforce Staylong Gel, Unwanted 72, Prega News, Gas-O-Fast, Kaloree 1, Kabzend, Acne Star Gel and many others. Our operations are in 34 overseas destinations across Asia, Africa, South-East Asia, Gulf countries and CIS countries. Our Vision - To be a global pharmaceutical company, most admired for its Affordability, Quality and Accessibility of products. Our Mission - To be able to provide cost-effective, innovation based superior quality pharmaceutical products across the globe, to improve the lives of the patients. Mankind strongly believes and follows its Core Values: 𝐂𝐮𝐬𝐭𝐨𝐦𝐞𝐫 𝐂𝐞𝐧𝐭𝐫𝐢𝐜𝐢𝐭𝐲: Commitment to Customer - Internal and External 𝐐𝐮𝐚𝐥𝐢𝐭𝐲: It is in our DNA to maintain and deliver highest quality standards and products 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧: Intensely Research driven organization aiming at product innovation and technology improvements 𝐈𝐧𝐭𝐞𝐠𝐫𝐢𝐭𝐲: Always trustworthy, widely respected to be honest, and believed by everyone 𝐆𝐨 𝐁𝐞𝐲𝐨𝐧𝐝: Aim higher than capabilities 𝐏𝐞𝐨𝐩𝐥𝐞 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐚𝐧𝐝 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧: Together we are foreseeing future and diligently stimulating our people in attaining goals

PT Kalbe Farma, Tbk

kalbe.co.id

Established in 1966, PT Kalbe Farma Tbk. (“the Company” or “Kalbe”) has gone a long way from its humble beginnings as a garage-operated pharmaceutical business in North Jakarta. It has expanded by strategic acquisitions of pharmaceutical companies, building a leading brand positioning and reaching to international markets to transform itself into an integrated consumer health and nutrition enterprise to promote its mission to improve health for a better life. Kalbe expands its business interests and transformed itself to become a provider of an integrated healthcare solution through its 4 business divisions: the Prescription Pharmaceutical Division, Consumer Health Division, Nutritionals Division and Distribution and Logistics Division. These business divisions manage an extensive portfolio of prescription pharmaceuticals and OTC drugs, energy drink and nutrition products, as well as a robust distribution arm serving over one million outlets across Indonesia’s vast archipelago. In the international market, the Company has established its footprint in ASEAN countries, Nigeria, and South Africa, positioning Kalbe as a national pharmaceutical company with a competitive edge in the export market. Kalbe Farma has established a robust research and development activities in leading edge generic drug formulation and continuous development of innovative consumer and nutritional products. Through strategic alliances with international partners, Kalbe have also started to support several successful research and development venture working on cancer drugs, stem cells and biotechnology research. With 17,000 employees, Kalbe Farma is the largest healthcare provider in Indonesia, with unrivaled marketing, branding, distribution, financial strength and research and development expertise. Kalbe Farma is also the largest publicly-listed pharmaceutical company in Southeast Asia, commanding a market capitalization of Rp71.0 trillion and sales turnover Rp21.0 trillion by end of 2018.

MENARINI Group

menarini.com

The Menarini Group is a leading international pharmaceutical and diagnostics company, with 140 years of history, present in 140 countries worldwide, with a turnover of 4.88 billion euro and more than 17,000 employees. With 9 centers for Research & Development, Menarini’s products are present in the most important therapeutic areas, including cardiology, oncology, gastroenterology, pneumology, diabetes, and anti-inflammatory/analgesics. The Group’s pharmaceutical production is carried out in its 18 manufacturing plants and is distributed across six continents. Menarini’s pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health of patients all over the world. For further information, please visit www.menarini.com For reading our Netiquette, please visit https://www.menarini.com/en-us/data-privacy/netiquette-of-menarini-group For reading our Privacy Notice for social networks users, please visit https://www.menarini.com/en-us/data-privacy/privacy-notice-for-social-network-users-of-menarini-group

Eli Lilly and Company

lilly.com

We're a medicine company turning science into healing to make life better for people around the world. It all started nearly 150 years ago with a clear vision from founder Colonel Eli Lilly: "Take what you find here and make it better and better." Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing science to solve some of the world's most significant health challenges. General Information and Guidelines: When you engage with us on LinkedIn, you're agreeing to these Community Guidelines: https://e.lilly/guidelines. If you have questions about a Lilly medicine, contact The Lilly Answers Center at 1-800-Lilly-Rx (1-800-545-5979) Monday through Friday, excluding company holidays.

Johnson & Johnson Innovative Medicine

jnj.com

At Johnson & Johnson Innovative Medicine, we innovate with purpose, to lead where medicine is going. The experiences of patients around the world inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science with compassion, we confidently address the most complex diseases of our time and develop the potential medicines of tomorrow. We are continuously working to develop treatments, aspiring to find cures, pioneering the path from lab to life, and championing patients every step of the way. https://bit.ly/3reuMvK

Sandoz

sandoz.com

Sandoz is the global leader in generic and biosimilar medicines. Our Purpose is to pioneer access to medicines for patients globally. We are on a mission to drive innovation in the healthcare industry by freeing up resources sustainably and responsibly while continuing to address global health challenges such as antimicrobial resistance. We are present in more than 100 countries and our medicines serve some 500 million people every year. We have two main global businesses: Generics - divided between standard generics and complex generics - and Biosimilars. Read our community engagement guidelines: http://bit.ly/4ofoggc

SUN PHARMA

sunpharma.com

Sun Pharma is the world's fourth-largest speciality generic pharmaceutical company and No. 1 in India. We provide high-quality, affordable medicines trusted by customers and patients in over 100 countries. Sun Pharma's global presence is supported by more than 40 manufacturing facilities spread across 5 continents, R&D centres across the globe, and a multicultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities comprising around 3,000 scientists and R&D investments of over 6-8% of annual revenues. At Sun, our people are our greatest asset. Ours has never been a story of individual brilliance but of cultivating a culture of realising collective potential. In our journey, everyone is enabled to take charge in an environment that offers limitless growth opportunities. We are with you every step of the way, so you can shine for years to come. With the launch of our Employee Value Proposition (EVP), we define our promise to ‘Create Your Own Sunshine'—driven by the three pillars of Better Every Day, Take Charge, and Thrive Together. These pillars drive progress at Sun so that people can achieve what they would have thought impossible. Learn more about our EVP here: https://sunpharma.com/careers/

AbbVie

cb abbvie.com

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.

Lupin

lupin.com

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

Loading…

NEWS

Intertek Pharmaceutical Services CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

January 08, 2025 04:48 AM

U.S. Pharmaceutical Packaging Services Market Report, 2030

The U.S. pharmaceutical packaging services market size was estimated at USD 2.82 billion in 2024 and is expected to expand at a CAGR of 9.0% from 2025 to...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-77684

SUMMARY

The Bluetooth Classic Hands-Free Profile HF role in subsys/bluetooth/host/classic/hfp_hf.c does not release the AT command buffers that are still queued on hf->tx_pending when the RFCOMM DLC goes down. hfp_hf_disconnected() only cancelled the work items and cleared hf->acl, and no other code path ever dequeues those buffers, so each one is permanently lost from the fixed hf_pool (CONFIG_BT_MAX_CONN + 1 buffers, i.e. two in the default configuration). The same function also left BT_HFP_HF_FLAG_CONNECTED set, and hfp_hf_create() wiped the object with memset() as soon as hf->acl was NULL, without checking whether hf->work, hf->slc_work or hf->deferred_work was still pending or running. The remote Audio Gateway peer controls the trigger end to end and needs no application involvement: an unsolicited +BCS: 1 response makes bcs_handle() call bt_hfp_hf_select_codec() and queue an AT+BCS buffer, which cannot be transmitted while BT_HFP_HF_FLAG_RX_ONGOING is set, and an immediately following RFCOMM DISC strands that buffer. Repeating the connect / +BCS / disconnect cycle a couple of times empties hf_pool for good. With the pool exhausted, HFP command sending fails permanently, and because hfp_hf_send_cmd() allocates with K_FOREVER (bt_rfcomm_create_pdu() → bt_conn_create_pdu()) from the Bluetooth RX context — where that timeout is not downgraded to K_NO_WAIT — one further +BCS from the peer parks the Bluetooth RX thread inside net_buf_alloc() with no possible waker, halting all HCI event processing until the device is rebooted. Separately, reusing the HF slot while a work handler was still queued or running allowed memset() to wipe live k_work items out from under the system workqueue, corrupting shared kernel workqueue state. Exploitation requires an established HFP session (for SSP devices L2CAP enforces authentication before the RFCOMM channel is reachable) and a build with CONFIG_BT_HFP_HF enabled.

Published

Date2026-10-19

Updated

Date2026-10-19

RISK INFORMATION (Score: 5.7)

cvss3

Base Score: 5.7

Complexity: LOW

CVSS:3.1/AV:A/AC:L/PR:L/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

2.1

REFERENCES

CVE-2026-19595

SUMMARY

The user-mode syscall verifier z_vrfy_rtio_cqe_get_mempool_buffer() in subsys/rtio/rtio_syscalls.c validated its two output parameters, buff and buff_len, with K_SYSCALL_MEMORY_READ() rather than K_SYSCALL_MEMORY_WRITE(). Both are pure out-parameters: z_impl_rtio_cqe_get_mempool_buffer() stores the mempool buffer address and its length through them. The distinction is enforced by every architecture validator — arch_buffer_validate() on RISC-V PMP explicitly accepts the global __rom_region/__rodata_region for reads only, and the ARM MPU validators accept P_RO_U_RO and P_RW_U_RO regions for reads only — so a read-validated pointer is not necessarily writable by the calling thread. An unprivileged user-mode thread that has been granted access to an RTIO context (rtio_access_grant()) can invoke the rtio_cqe_get_mempool_buffer() syscall with buff/buff_len pointing at memory it may read but not write, and with a completion-queue entry whose flags field it fully controls (only RTIO_CQE_FLAG_MEMPOOL_BUFFER in flags[7:0] is required; flags[19:8] and flags[31:20] supply the block index and count). The kernel then performs a pointer-sized and a 4-byte store through those addresses while running in supervisor mode. Reaching the store requires CONFIG_USERSPACE together with CONFIG_RTIO_SYS_MEM_BLOCKS, the configuration behind RTIO_DEFINE_WITH_MEMPOOL; without the latter the implementation returns -ENOTSUP and writes nothing. Two outcomes follow. If the target lies in a memory-domain partition declared K_MEM_PARTITION_P_RW_U_RO (privileged read-write, user read-only), the kernel-mode store succeeds and deposits partly attacker-chosen values into memory the memory domain had marked read-only for that thread, bypassing the partition's write protection. If the target lies in globally readable but unwritable memory such as .text/.rodata in flash, the store faults in kernel mode; the fault is delivered to z_fatal_error() and the default k_sys_fatal_error_handler() halts or reboots the device, giving an unprivileged thread a reliable full denial of service. The read-permission check does bound the damage: the address must still be readable by the calling thread, so kernel-private memory cannot be targeted and no confidential data is disclosed. The fix replaces both checks with K_SYSCALL_MEMORY_WRITE(), so a thread lacking write permission is terminated by K_OOPS before the implementation runs; the cqe argument correctly remains read-validated.

Published

Date2026-10-19

Updated

Date2026-10-19

RISK INFORMATION (Score: 6.1)

cvss3

Base Score: 6.1

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:U/C:N/I:L/A:H

Impact Score

4.2

Exploitability

1.8

REFERENCES

CVE-2026-19178

SUMMARY

IBM Storage TS4500 Library 1.1.1.6 through 1.12.0.3 could allow a remote authenticated attacker to gain unauthorized administrative privileges due to a race condition.

Published

Date2026-10-19

Updated

Date2026-10-19

RISK INFORMATION (Score: 6.8)

cvss3

Base Score: 6.8

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:L/UI:N/S:U/C:H/I:H/A:N

Impact Score

5.2

Exploitability

1.6

REFERENCES

https://www.ibm.com/support/pages/node/7292610

CVE-2026-112991

SUMMARY

The html_to_markdown expansion module in MISP Modules contains a server-side request forgery (SSRF) vulnerability in its is_safe_url() URL validation function. The BLOCKED_RANGES list used to reject unsafe destination addresses was incomplete, omitting several critical IP address ranges. Specifically, the following ranges were not blocked: 0.0.0.0/8 (unspecified, which routes to loopback on Linux), 100.64.0.0/10 (carrier-grade NAT per RFC 6598), ::/128 (IPv6 unspecified), fc00::/7 (IPv6 Unique Local Addresses), and fe80::/10 (IPv6 link-local). The existing list only covered IPv4 loopback (127.0.0.0/8), RFC 1918 private ranges, IPv4 link-local (169.254.0.0/16), and IPv6 loopback (::1/128). An authenticated user with the ability to create or modify MISP attributes that trigger the html_to_markdown expansion module could supply URLs pointing to these unblocked internal address ranges. Because the module fetches the URL server-side to convert HTML content to Markdown, the request is made from the MISP server's network context. This allows an attacker to probe and read responses from internal services, carrier-grade NAT infrastructure, or link-local endpoints that would otherwise be unreachable from external networks. IPv4-mapped IPv6 forms (e.g., [::ffff:0.0.0.0]) also bypassed the existing checks. The security impact is primarily confidentiality: an attacker can read data served by internal services reachable from the MISP server. The MISP instance itself is not compromised, but it is abused as a proxy to access otherwise restricted network resources.

Published

Date2026-10-19

Updated

Date2026-10-19

RISK INFORMATION (Score: )

cvss4

Base Score: 6.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:N/VI:N/VA:N/SC:H/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

https://github.com/misp/misp-modules/commit/98a1c2c2f297665dd8d4609e9cd644007a57516b

CVE-2026-112372

SUMMARY

A weakness has been identified in H3C Magic NX15 V100R017. This affects the function importprofile of the file /api/upload. This manipulation of the argument fileName causes path traversal. It is possible to initiate the attack remotely. The exploit has been made available to the public and could be used for attacks. The vendor was contacted early about this disclosure.

Published

Date2026-10-19

Updated

Date2026-10-19

RISK INFORMATION (Score: 6.6)

cvss2

Base Score: 5.8

Complexity: LOW

AV:N/AC:L/Au:M/C:P/I:P/A:P

cvss3

Base Score: 6.6

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:H/UI:N/S:C/C:L/I:L/A:L

cvss4

Base Score: 2.0

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:H/UI:N/VC:L/VI:L/VA:L/SC:L/SI:L/SA:L/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.7

Exploitability

2.3

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…

Badge your company to reduce your risk score and your cyber insurance costs!

Trusted by insurers. Chosen by leaders.

Intertek Pharmaceutical Services Vendor Cyber Rating & Cyber Score

IPS A.I CyberSecurity Scoring

Intertek Pharmaceutical Services CyberSecurity News & History

IPS Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for IPS

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types IPS vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - IPS (X = Date, Y = Severity)

Intertek Pharmaceutical Services Subsidiaries

IPS

Intertek Pharmaceutical Services Similar Companies

MANKIND PHARMA LTD

PT Kalbe Farma, Tbk

MENARINI Group

Eli Lilly and Company

Johnson & Johnson Innovative Medicine

Sandoz

SUN PHARMA

AbbVie

Lupin

Intertek Pharmaceutical Services CyberSecurity News

U.S. Pharmaceutical Packaging Services Market Report, 2030

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo

Intertek Pharmaceutical Services CyberSecurity News & History

IPS Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for IPS

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types IPS vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - IPS (X = Date, Y = Severity)

Intertek Pharmaceutical Services Subsidiaries

IPS

Intertek Pharmaceutical Services Similar Companies

MANKIND PHARMA LTD

PT Kalbe Farma, Tbk

MENARINI Group

Eli Lilly and Company

Johnson & Johnson Innovative Medicine

Sandoz

SUN PHARMA

AbbVie

Lupin

Intertek Pharmaceutical Services CyberSecurity News

U.S. Pharmaceutical Packaging Services Market Report, 2030

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo